<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-113285</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Antiangiogenic therapy in Sorsby's fundus dystrophy without a mutation in the TIMP-3 gene</dc:title>
<dc:description xml:lang="en">Case report: The case is presented of a 32-year-old man referring to metamorphopsia and blurred vision in both eyes for 3 days. Best corrected visual acuity of 20/32 in the right eye and 20/25 in the left eye. Fundus examination revealed the presence of drusen-like deposits, suggestive of Sorsby's fundus dystrophy (SFD) and choroidal neovascularization (CNV) bilaterally. The patient received intravitreal ranibizumab. Visual acuity improved to 20/20 in both eyes at 6-months follow-up, and results of fundus examination showed complete regression of neovascularization. No mutations were found in the TIMP-3 gene. Discussion: The known mutations in TIMP-3 may not be extended to all patients with SFD. The use of intravitreal ranibizumab may be considered as a therapeutic option in CNV secondary to SFD (AU)</dc:description>
<dc:creator>Flores-Moreno, I</dc:creator>
<dc:creator>Moreno-Valladares, A</dc:creator>
<dc:creator>Bautista Ruescas, V</dc:creator>
<dc:creator>Cava-Valenciano, C</dc:creator>
<dc:creator>Copete-Piqueras, S</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Varón de 32 años, con metamorfopsias y visión borrosa bilateral de tres días de evolución. Mejor agudeza visual corregida de 20/32 en OD y 20/25 en OI. La funduscopia presenta lesiones amarillentas difusas sugerentes de distrofia de Sorsby y membranas neovasculares (MNV). Recibió tratamiento con ranibizumab intravítreo, mejorando la agudeza visual a 20/20 en ambos ojos y remitiendo las MNV. No se hallaron mutaciones conocidas de TIMP-3. Discusión: Las mutaciones conocidas en TIMP-3 pueden no estar extendidas a todos los pacientes con fondo de distrofia de Sorsby. El ranibizumab intravítreo debe considerarse para el tratamiento de MNV secundaria a esta enfermedad (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;88(6): 240-243, jun. 2013. ilus</dc:source>
<dc:identifier>ibc-113285</dc:identifier>
<dc:title xml:lang="es">Tratamiento antiangiogénico en fondo de distrofia de Sorsby sin mutación en gen de TIMP-3</dc:title>
<dc:subject>^d331</dc:subject>
<dc:subject>^d38335^s22074</dc:subject>
<dc:subject>^d30179^s22057</dc:subject>
<dc:subject>^d34460^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d53976^s22057</dc:subject>
<dc:subject>^d33428^s22033</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:type>article</dc:type>
<dc:date>201306</dc:date>
</metadata>
</record>
</ibecs-document>
